BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells

Clinical Cancer Research

Volumn 9, Issue 11, 2003, Pages 4267-4273

  Tauchi, Tetsuzo ^a   Sumi, Masahiko ^a   Nakajima, Akihiro ^a   Sashida, Goro ^a   Shimamoto, Takashi ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; G 3622; IMATINIB; MESSENGER RNA; OBLIMERSEN; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL FRACTIONATION; CONTROLLED STUDY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; NUDE MOUSE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TUMOR CELL CULTURE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; LEUKEMIA, MYELOID; MICE; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES; SURVIVAL ANALYSIS; THIONUCLEOTIDES; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0141790036     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Tauchi, T., and Broxmeyer, H. E. BCR/ABL signal transduction, Int. J. Hematol., 61: 105-112, 1995.
2. Konopka, J. B., Watanabe, S. M., and Witte, O. N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell, 37: 1035-1042, 1984.
3. Kloetzer, W., Kurzrock, R., Smith, L., Talpaz, M., Spiller, M., Gutterman, J., and Arlinghaus, R. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology, 140: 230-238, 1985.
4. Thiesing, J. T., Ohno-Jones, S., Kolibaba, K. S., and Druker, B. J. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood, 96: 3195-3199, 2000.
5. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat. Med., 2: 561-566, 1996.
6. Nakajima, A., Tauchi, T., and Ohyashiki, K. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. Leukemia (Baltimore), 15: 989-990, 2001.
7. Savage, D. G., and Antman, K. H. Imatinib mesylate - a new oral targeted therapy. N. Engl. J. Med., 346: 683-693, 2002.
8. Cotter, F. E., Johnson, P., Hall, P., Pocock, C., al Mahdi, N., Cowell, J. K., and Morgan, G. Antisense oligonucleotides suppress B-cell lymphoma growth in SCID-hu mouse model. Oncogene, 9: 3049-3055, 1994.
9. Ranger, A. M., Malynn, B. A., and Korsmeyer, S. J. Mouse models of cell death. Nat. Genet., 28: 113-118, 2001.
10. Zamzami, N., Brenner, C., Marzo, I., Susin, S. A., and Kroemer, G. Subcellular and submitochondrial model of action of Bcl-2 like oncoprotein. Oncogene, 16: 2265-2282, 1998.
11. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapeutic-induced apoptosis in a human leukemia cell line. Blood, 81: 151-157, 1993.
12. Reed, J. C. Bcl-2 prevention of apoptosis as a mechanism of drug resistance. Hematol. Oncol. Clin. N. Am., 9: 451-473, 1995.
13. Reed, J. C., Miyashita, T., Takayama, S., Wang, H. G., and Sato, T., Krajewski, S., Aime-Sempe, C., Bodrug, S., Kitada, S., and Hanada, M. Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell. Biochem., 60: 23-32, 1996.
14. Salomoni, P., Condorelli, F., Sweeney, S. M., and Calabretta, B. Versatility of BCR-ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood, 96: 676-684, 2000.
15. Cirinna, M., Trotta, R., Salomoni, P., Kossev, P., Wasik, M., Perrotti, D., and Calabretta, B. Bcl-2 expression restores the leukemogenetic potential of a BCR-ABL mutant defective in transformation. Blood, 96: 3915-3921, 2000.
16. Raynaud, F. I., Orr, R. M., Goddard, P. M., Lacey, H. A., Lancashire, H., Judson, I. R., Beck, T., Bryan, B., and Cotter, F. E. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense of bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J. Pharmacol. Exp. Ther., 281: 420-427, 1997.
17. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349: 1137-1141, 1997.
18. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elsas, A., Muller, M., Wolff, K., Eichler, H. G., and Pehamberger, H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med., 4: 232-234, 1998.
19. Jansen, B., Wacheck, V., Heere-Ress, E., Schlagbauer-Wadl, H., Hoeller, C., Lucas, T., Hoermann, M., Wolff, K., and Pehamberger, H. Chemosensitisation of malignant melanoma by BCL-2 antisense therapy. Lancet, 356: 1728-1733, 2000.
20. Lopes de Menezes, D. E., Hudon, N., McIntosh, N., and Mayer, L. D. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin. Cancer Res., 6: 2891-2902, 2000.
21. Miyake, H., Tolcher, A., and Gleave, M. E. Chemosentisization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J. Natl. Cancer Inst., 92: 34-41, 2000.
22. Wacheck, V., Heere-Ress, E., Halaschek-Wiener, J., Lucas, T., Meyer, H., Eichler, H. G., and Jansen, B. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J. Mol. Med., 79: 587-593, 2001.
23. Chi, K. N., Gleave, M. E., Klasa, R., Murray, N., Bryce, C., Lopes de Menezes, D. E., D'Aloisio, S., and Tolcher, A. W. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res., 7: 3920-3927, 2001.
24. Lopes, D., and Mayer, L. D. Phamacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother. Pharmacol., 49: 57-68, 2002.
25. Rudin, C. M., Otterson, G. A., Mauer, A. M., Villalona-Calero, M. A., Tomek, R., Prange, B., Geoge, C. M., Szeto, L., and Vokes, E. E. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann. Oncol., 13: 539-545, 2002.
26. Marcucci, G., Byrd, J. C., Dai, G., Klisovic, M. I., Youg, D. C., Cataland, S. R., Fisher, D. B., Lucas, D., Chan, K. K., Porcu, P., Lin, Z. P., Farag, S. F., Frankel, S. R., Zweibel, J. A., Kraut, E. H., Balcerzak, S. P., Bloomfield, C. D., Grever, M. R., and Caligiuri, M. A. Phase I and pharmacodynamic studies of G3139, a bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood, 102: 425-432, 2003.
27. Tauchi, T., Ohyashiki, K., Yamashita, Y., Sugimoto, S., and Toyama, K. SH2-containing phosphotyrosine phosphatase SHP-1 is involved in BCR-ABL signal transduction pathways. Int. J. Oncol., 11: 471-475, 1997.
28. Tauchi, T., Yoshimura, A., and Ohyashiki, K. CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation: Involvement of the ubiquitin proteasome pathway. Exp. Hematol., 29: 356-361, 2001.
29. Tauchi, T., Nakajima, A., Sashida, G., Shimamoto, T., Ohyashiki, J. H., Abe, K., Yamamoto, K., and Ohyashiki, K. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin. Cancer Res., 8: 3341-3347, 2002.